AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$PAHC

Phibro Animal Health (NASDAQ:PAHC) exceeds Q3 CY2026 expectations

Phibro Animal Health (PAHC) reported Q3 CY2026 revenue of $386.8M, beating estimates by 3% and growing 6.3% year-on-year. Adjusted EPS met expectations at $0.79. Adjusted EBITDA rose 3.9% to $64.3M. The company reconfirmed its full-year revenue guidance of $1.58B and adjusted EPS guidance of $3.50, with EBITDA guidance of $263M, above analyst estimates.

Original reporting
finance.yahoo.com
Published Nov 4, 2026, 9:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 10:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Phibro Animal Health (NASDAQ:PAHC) exceeds Q3 CY2026 expectations — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$PAHCNeutralHigh
01

Why it matters

The earnings beat provides a short‑term catalyst, but unchanged guidance limits long‑term upside.

02

Market read

Earnings release offers a trading opportunity for PAHC; sector impact modest.

03

What to watch

Operating margin decline and year‑on‑year margin compression may signal cost pressures.

Relevance 8/10Novelty 8/10Timing: post-market today

Background

Phibro Animal Health reported Q3 2026 results, beating revenue estimates and reaffirming full-year outlook.

Company-level read

Ticker impact

$PAHCNeutralHigh confidence
Context

Q3 2026 earnings beat revenue estimates and reaffirmed full-year guidance.

Expected impact

slight upward pressure as the beat may attract buyers, but unchanged guidance caps gains

Evidence & confidence

Revenue beat indicates operational strength, yet guidance unchanged signals management caution, limiting upside.

Market effects

Sector

Animal health sector may see modest confidence boost from beat, but guidance stability tempers broader rally.

Regional

U.S. small-cap investors may adjust positions in health‑related stocks.

Global

Limited, as company is niche and impact confined to sector.

Counterpoint

What could challenge this read

Flat guidance suggests potential downside if market expects higher growth; price could slip on disappointment.

Key entities

  • Company
    Phibro Animal Health

    NASDAQ‑listed animal health products manufacturer.

Read at source← All news

Related articles

$PAHCMedAI 8/10

Phibro Animal (PAHC) Q1 2027 Earnings Call Transcript

Phibro Animal Health (PAHC) reported Q1 2027 sales growth of 6% to $386.8M and adjusted EBITDA growth of 4% to $64.3M. Performance Products and Mineral Nutrition segments drove growth, while Animal Health saw a 3% increase. The company maintained its full-year guidance and expects protein demand to grow, despite near-term pressure on producer profitability.

finance.yahoo.com
$PAHCHighAI 8/10

Phibro Animal Health Corp (PAHC) (Q1 2027) Earnings Call Highlights: Solid Start to Fiscal

Phibro Animal Health (PAHC) reported Q1 2027 sales of $386.8M (+6%) and adjusted EBITDA of $64.3M (+4%). CEO Donnie Bantine expects Brazil Virginiamycin approval but no sales assumed in 2027. Zoetis portfolio drove MFA growth, while livestock margins are squeezed. USDA's border reopening impacts cattle imports. Net income rose 11% to $29.5M. Guidance remains unchanged, with net sales expected between $1.55B-$1.6B.

finance.yahoo.com
$PAHCMed

What Phibro Animal Health (PAHC) Said on Its Q1 Earnings Call

Phibro Animal Health (PAHC) reported Q1 adjusted EBITDA fell $1M due to higher SG&A expenses, despite increased gross profit. Mineral Nutrition and Performance Products sales rose 17% and 16%, respectively, with EBITDA gains. Companywide operating income declined $1.6M. Phibro maintained fiscal 2027 guidance, with net sales expected between $1.55B and $1.6B. Brazilian regulatory discussions continue, with no sales included in the forecast. Free cash flow was $22M over the past year.

finance.yahoo.com
$PAHCMed

Phibro Animal Health Corporation Reports First Quarter Results, Maintains Financial Guidance

PHIBRO ANIMAL HEALTH CORP (PAHC) filed an SEC Form 8-K — Results of Operations and Financial Condition. ​ Exhibit 99.1 ​ ​ For Immediate Release ​ Phibro Animal Health Corporation Reports First Quarter Results, Maintains Financial Guidance ​ TEANECK, N.J., November 4, 2026 (Business Wire) – Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced

SEC EDGAR 8-K
$PAHCMedAI 8/10

Phibro Animal Health (PAHC) Sets 2027 Guidance, Is The Stock Still A Bargain?

Phibro Animal Health (PAHC) issued 2027 guidance, projecting net sales of $1.55b-$1.60b and net income of $122m-$132m. The company reported 2026 sales of $1.518b and net income of $99.72m. Analysts' price targets range from $38 to $58, with a consensus of $45.60, suggesting a 16.1% undervaluation. The stock has seen a 90-day return of 17.95% and a 3-year return above 200%.

yahoo.com